健康元药业集团股份有限公司关于聘任公司副总裁的公告

Core Viewpoint - The company has appointed Mr. Zhang Qinglei as the Vice President to accelerate the research and commercialization of innovative drugs, effective from the date of the board's approval until the end of the current board's term [1]. Group 1: Appointment Details - The board of directors approved the appointment of Mr. Zhang Qinglei as Vice President, who will be responsible for regulatory affairs related to drug policies and will promote clinical research applications and new drug listings [1]. - Mr. Zhang was nominated by the company's president and passed the qualifications review by the board's nomination committee [1]. Group 2: Qualifications and Background - Mr. Zhang does not hold any shares in the company and has no relationships with major shareholders or other executives [2]. - He possesses the necessary qualifications and experience required for the role, complying with the company's articles of association and relevant laws [2]. - Mr. Zhang has a strong background in drug registration and regulatory policy, having previously worked at several pharmaceutical companies before joining the company in February 2019 [5].